X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (297) 297
Publication (21) 21
Patent (9) 9
Conference Proceeding (7) 7
Book Chapter (3) 3
Book / eBook (2) 2
Dissertation (1) 1
Journal / eJournal (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (122) 122
index medicus (80) 80
male (71) 71
female (65) 65
middle aged (57) 57
aged (55) 55
venous thromboembolism (50) 50
prevention (47) 47
anticoagulants - therapeutic use (44) 44
risk factors (44) 44
thromboembolism (41) 41
anticoagulants (40) 40
adult (39) 39
thrombosis (38) 38
hematology (37) 37
peripheral vascular disease (34) 34
cancer (33) 33
atrial fibrillation (32) 32
treatment outcome (32) 32
abridged index medicus (30) 30
deep-vein thrombosis (30) 30
neoplasms - complications (29) 29
venous thromboembolism - prevention & control (29) 29
stroke (28) 28
oncology (26) 26
prophylaxis (26) 26
rivaroxaban (26) 26
warfarin (26) 26
care and treatment (25) 25
double-blind method (24) 24
hemorrhage - chemically induced (24) 24
surgery (24) 24
drug therapy (22) 22
mortality (22) 22
medicine, general & internal (21) 21
anticoagulants - adverse effects (20) 20
cardiac & cardiovascular systems (20) 20
molecular-weight heparin (20) 20
patients (20) 20
aged, 80 and over (18) 18
anticoagulants - administration & dosage (18) 18
venous thromboembolism - drug therapy (18) 18
venous thrombosis (18) 18
bleeding (17) 17
pulmonary embolism (17) 17
risk (17) 17
risk assessment (17) 17
heparin (16) 16
heparin, low-molecular-weight - therapeutic use (16) 16
pulmonary-embolism (16) 16
therapy (16) 16
venous thromboembolism - etiology (16) 16
venous thrombosis - prevention & control (16) 16
administration, oral (15) 15
enoxaparin (15) 15
hemorrhage (15) 15
prospective studies (15) 15
pulmonary embolism - prevention & control (15) 15
unfractionated heparin (15) 15
dosage and administration (14) 14
health aspects (14) 14
management (14) 14
recurrence (14) 14
registries (14) 14
time factors (14) 14
fibrinolytic agents - therapeutic use (13) 13
thromboprophylaxis (13) 13
guidelines (12) 12
postoperative complications - prevention & control (12) 12
anticoagulation (11) 11
chemotherapy (11) 11
health risk assessment (11) 11
incidence (11) 11
life sciences (11) 11
practice guidelines as topic (11) 11
research (11) 11
usage (11) 11
analysis (10) 10
cardiac arrhythmia (10) 10
cardiovascular (10) 10
diagnosis (10) 10
internal medicine (10) 10
neoplasms - drug therapy (10) 10
neoplasms - mortality (10) 10
pulmonary embolism - mortality (10) 10
veins & arteries (10) 10
venous thromboembolism - epidemiology (10) 10
adolescent (9) 9
atrial fibrillation - drug therapy (9) 9
fibrinolytic agents - adverse effects (9) 9
follow-up studies (9) 9
human necessities (9) 9
hygiene (9) 9
medical or veterinary science (9) 9
medicine (9) 9
preparations for medical, dental, or toilet purposes (9) 9
randomized controlled trials as topic (9) 9
thromboembolism - prevention & control (9) 9
warfarin - therapeutic use (9) 9
clinical neurology (8) 8
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2004, 1, ISBN 9781841842875, 241
It is common knowledge that thromboembolic disease is often the earliest manifestation and almost the most frequent complication of cancer. Recent studies have... 
Complications | Thrombosis | Cancer | Clinical & internal medicine
eBook
The New England Journal of Medicine, ISSN 0028-4793, 06/2008, Volume 358, Issue 26, pp. 2765 - 2775
Rivaroxaban is an orally administered direct inhibitor of factor Xa. As compared with enoxaparin, rivaroxaban was more effective in preventing venous... 
ORAL XIMELAGATRAN | MEDICINE, GENERAL & INTERNAL | FACTOR-XA INHIBITOR | KNEE REPLACEMENT | BAY-59-7939 | DEEP-VENOUS THROMBOSIS | MOLECULAR-WEIGHT HEPARIN | MAJOR ORTHOPEDIC-SURGERY | DOUBLE-BLIND | PREVENTION | THROMBOEMBOLISM | Thiophenes - therapeutic use | Pulmonary Embolism - prevention & control | Venous Thromboembolism - mortality | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Middle Aged | Male | Enoxaparin - therapeutic use | Pulmonary Embolism - epidemiology | Enoxaparin - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Aged, 80 and over | Adult | Female | Venous Thrombosis - prevention & control | Morpholines - adverse effects | Morpholines - therapeutic use | Double-Blind Method | Anticoagulants - therapeutic use | Arthroplasty, Replacement, Hip | Anticoagulants - adverse effects | Venous Thrombosis - epidemiology | Adolescent | Aged | Enoxaparin | Dosage and administration | Blood coagulation factors | Comparative analysis | Health aspects | Hip joint | Clinical trials | Comparative studies | Joint surgery | Drug therapy | Clinical outcomes | Blood clots | Index Medicus | Abridged Index Medicus | Enoxaparin/adverse effects/therapeutic use | Venous Thrombosis/epidemiology/prevention & control | Thiophenes/adverse effects/therapeutic use | Arthroplasty | Replacement | Kirurgi | Hip | Morpholines/adverse effects/therapeutic use | 80 and over | Surgery | Anticoagulants/adverse effects/therapeutic use | Venous Thromboembolism/mortality/prevention & control | Factor Xa/antagonists & inhibitors | Pulmonary Embolism/epidemiology/prevention & control
Journal Article
Plos One, ISSN 1932-6203, 2013, Volume 8, Issue 5, p. e63479
Journal Article
Lancet, The, ISSN 0140-6736, 2008, Volume 372, Issue 9632, pp. 31 - 39
Summary Background The risk of venous thromboembolism is high after total hip arthroplasty and could persist after hospital discharge. Our aim was to compare... 
Internal Medicine | WEIGHT HEPARIN-PROPHYLAXIS | MEDICINE, GENERAL & INTERNAL | PLACEBO | FACTOR-XA INHIBITOR | ORTHOPEDIC-SURGERY | KNEE REPLACEMENT | BAY-59-7939 | THROMBOSIS | PROLONGED THROMBOPROPHYLAXIS | TIME-COURSE | DALTEPARIN | Thiophenes - therapeutic use | Double-Blind Method | Drug Administration Schedule | Thiophenes - adverse effects | Humans | Middle Aged | Morpholines - administration & dosage | Arthroplasty, Replacement, Hip | Male | Thiophenes - administration & dosage | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Fibrinolytic Agents - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Enoxaparin - administration & dosage | Fibrinolytic Agents - therapeutic use | Aged, 80 and over | Adult | Female | Aged | Fibrinolytic Agents - administration & dosage | Morpholines - adverse effects | Morpholines - therapeutic use | Health care | Medical imaging | Hospitals | Protease inhibitors | Surgery | Tomography | Joint surgery | Drug therapy | Patients | Veins & arteries | Index Medicus | Abridged Index Medicus | Thiophenes/administration & dosage/adverse effects/therapeutic use | use | Arthroplasty | Replacement | Venous Thromboembolism/prevention & control | Morpholines/administration & dosage/adverse effects/therapeutic use | Kirurgi | Hip | 80 and over | Enoxaparin/administration & dosage/adverse effects/therapeutic use | Fibrinolytic Agents/administration & dosage/adverse effects/therapeutic
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2017, Volume 377, Issue 14, pp. 1319 - 1330
Journal Article